Mary Scoviak, Managing Editor

Once synonymous with puberty, acne is a growing concern for adults—particularly for women—from the 20s to well into their 40s. Christopher Bunick, MD, PhD delved into treatment options for this increasing patient population at the American Academy of Dermatology 2022 Annual Meeting.

Incoming president Mark D Kaufmann, MD, FAAD, outlined his action plan for the specialty’s rapidly changing landscape in his plenary session speech at the American Academy of Dermatology 2022 Annual Meeting held March 25 to 29, 2022, in Boston, Massachusetts.

Experts detailed current evidence-based treatment guidelines for Merkel cell carcinoma at the 2022 American Academy of Dermatology (AAD)’s Annual meeting held March 25 to 29, 2022, in Boston, Massachusetts.

Zoe Diana Draelos, MD, FAAD, explains the method of using the color wheel to guide your patients nutrition to help skin, nails, and more.

In this video interview, Christopher Bunick, MD, PhD dives into the topic of congenital ichthyosis describing his talk on the skin condition at the American Academy of Dermatology 2022 Annual Meeting.

Christopher Bunick, MD, PhD, talked about his presentation at the 2022 American Academy of Dermatology Annual Meeting on acne, which included a review of updated information on acne and practice pearls.

Jashin Wu, MD, FAAD, the founder and course director of the 3rd Annual San Diego Dermatology Symposium, offers highlights of the gamechanging topics on the agenda for this in-person conference set for March 11-13, 2022, in San Diego, California. Watch to see more information about the presentations.

Clinical trials investigate biologics, JAK inhibitors, and additional systemic treatments as first-line alternatives to or adjuvant therapies alongside surgery.

Experts outline strategies for patient conversations around the black box warning.

Acne may be the most common skin condition in the United States, with various studies estimating that 79% to 95% of Americans aged 12 to 24 year’s experience at least a minor case, yet diagnosing, treating, and managing care for pediatric patients affected by acne has never been more complex.

Will Kirby, DO, FAOCD, takes an interstellar sidetrip from his Los Angeles-based dermatology practice to the byways of Tatooine for an appearance in Episode VI of this streaming series which airs February 2, 2022 on Disney+.

Vial’s newly launched contract research organization (CRO) addressed ways to surmount some of the biggest obstacles blocking increased speed and quality of clinical trials with an advisory board meeting at Maui Derm for Dermatologists 2022.

This episode of The Cutaneous Connection podcast, explores hair loss and hair treatment of patients with textured or tightly coiled hair. Candrice Heath, MD, FAAP, FAAD a dermatologist and assistant professor of dermatology at the Lewis Katz School of Medicine at Temple University, explains her experience and highlights how all dermatologists can improve their treatment plans.

Skin cancer dermoscopy is getting a hightech overhaul as the scope of innovation broadens from a singular focus on the stand-alone product to the development of a comprehensive medical, patient care, and workflow management platform.

Skin sensitivity will be a factor in vehicles for new treatments.

Long underserved by a narrow armamentarium, patients with pigmentary disorders could soon see a new wave of oral and topical solutions to treat even the most challenging cases.

The recent approval of a topical androgen receptor inhibitor fills a longtime need in acne treatment.

The past year gave dermatologists ample cause for both celebration and frustration as they looked forward to new drugs, devices, and technology to optimize patient care. Here, Dermatology Times® editorial advisory board members weigh in on the good, bad, and still-TBD changes that shaped the specialty during 2021.

Factors ranging from demographics to the COVID-19 pandemic are shifting the landscape of occupational dermatoses.

In this video interview, James Q Del Rosso, DO, tackles the clinical impact of JAK Inhibitors and how to deal with patient concern.

In this exclusive video interview, James Q Del Rosso, DO, gets into the details of JAK inhibitors, explaining how they work and cutting through the headlines around the treatments.

In a video for Dermatology Times®, Mark Lebwohl, MD, details how to match patients with the right psoriasis treatment for their specific needs.

In a video for Dermatology Times®, Mark Lebwohl, MD, discloses the tips he and other physicians gave to nurse practitioners and physicians assistants to better care for patients.

In this video interview, Mark Lebwohl, MD, explains the need and demand for the 2021 NP&PA Fall Clinical Dermatology Conference.

In this video interview, Mark Lebwohl, MD, explains why topicals for inflammatory conditions are vital for treatment.

In this video interview, Fatima Khan, MD, discusses how atopic dermatitis can be detrimental to pediatric patients sleep, how the condition can change as the patient gets older, and more.

In this video interview, Jeff Yu, MD, highlights key talking points from his session on regional dermatitis and rash from the American College of Allergy, Asthma & Immunology annual scientific meeting.

In this video interview, Jeff Yu, MD, talks about what he's looking forward to at the 2021 American College of Allergy, Asthma & Immunology (ACAAI) annual scientific meeting.

Sessions with a laser focus on dermatologic issues ranging from new JAK inhibitors to disparities in atopic dermatitis anchor the opening day of the 2021 American College of Allergy, Asthma & Immunology (ACAAI) annual scientific meeting.

FDA approval of ruxolitinib (Opzelura, Incyte) adds the first new topical anti-inflammatory to the atopic dermatitis (AD) armamentarium in 50 years, but boxed warnings raise questions.